高级检索
    王维奇, 程慧, 郭琳琳, 贺磊磊, 成杰. 卵巢癌组织中CTHRC1、VEGF表达及临床意义[J]. 徐州医科大学学报, 2020, 40(9): 640-644. DOI: 10.3969/j.issn.2096-3882.2020.09.004
    引用本文: 王维奇, 程慧, 郭琳琳, 贺磊磊, 成杰. 卵巢癌组织中CTHRC1、VEGF表达及临床意义[J]. 徐州医科大学学报, 2020, 40(9): 640-644. DOI: 10.3969/j.issn.2096-3882.2020.09.004
    shu
    ex＜x＞pression and clinical significance of CTHRC1 and VEGF in ovarian cancer[J]. Journal of Xuzhou Medical University, 2020, 40(9): 640-644. DOI: 10.3969/j.issn.2096-3882.2020.09.004
    Citation: ex＜x＞pression and clinical significance of CTHRC1 and VEGF in ovarian cancer[J]. Journal of Xuzhou Medical University, 2020, 40(9): 640-644. DOI: 10.3969/j.issn.2096-3882.2020.09.004
    shu

    卵巢癌组织中CTHRC1、VEGF表达及临床意义

    ex＜x＞pression and clinical significance of CTHRC1 and VEGF in ovarian cancer

      摘要
    • 摘要: 目的 探讨卵巢癌组织中三螺旋重复胶原蛋白1(CTHRC1)、血管内皮生长因子(VEGF)表达及其临床意义.方法 选取2012年1月—2017年1月徐州市中心医院保存的卵巢癌组织标本86例,同时选取正常卵巢组织80例,采用免疫组化染色法检测CTHRC1、VEGF的表达.结果 卵巢癌组织中CTHRC1和VEGF阳性表达率分别为67.44％和69.77％,明显高于正常卵巢组织(P<0.05);FIGO分期Ⅲ—Ⅳ期、病理分级G3、有淋巴结转移患者CTHRC1阳性表达率分别为96.43％、80.36％和90.32％,明显高于FIGO分期Ⅰ—Ⅱ、病理分级G1+G2、无淋巴结转移者(P<0.05);FIGO分期Ⅲ—Ⅳ期、有淋巴结转移患者VEGF阳性表达率分别为85.71％和90.32％,明显高于FIGO分期Ⅰ—Ⅱ、无淋巴结转移患者(P<0.05);卵巢癌组织中CTHRC1和VEGF的表达呈正相关(rs=0.515,P<0.05).结论 卵巢癌组织中CTHRC1、VEGF表达明显上调,可能与患者FIGO分期、病理分级以及淋巴结转移有关.同时CTHRC1和VEGF表达呈正相关,推测CTHRC1和VEGF对卵巢癌病情进展可能具有协同作用.

       

      Abstract: ob＜x＞jective: To investigate the ex＜x＞pression of triple helix repeat collagen 1 (CTHRC1) and vascular endothelial growth factor (VEGF) in ovarian cancer and its clinical significance. Methods: From January 2012 to January 2017, 86 ovarian cancer specimens and 80 normal ovarian tissues were selected, the ex＜x＞pressions of CTHRC1 and VEGF were detected by immunohistochemical staining. Results: The positive rates of CTHRC1 and VEGF protein in ovarian cancer tissues were 67.44% and 69.77% respectively, which were significantly higher than those in normal ovarian tissues (p < 0.05); The positive ex＜x＞pression rates of CTHRC1 protein in patients with FIGO stage III-IV, pathological grade G3 and lymph node me＜x＞tastasis were 96.43%, 80.36% and 90.32% respectively, which were significantly higher than those in patients with FIGO stage I-II, pathological grade G1+G2 and no lymph node me＜x＞tastasis (p < 0.05); The positive ex＜x＞pression rate of VEGF protein in patients with FIGO stage III-IV and lymph node me＜x＞tastasis were 85.71% and 90.32% respectively, which were significantly higher than that in patients with stage I-II FIGO and without lymph node me＜x＞tastasis (p < 0.05); The ex＜x＞pression of CTHRC1 and VEGF protein in ovarian cancer patients was positively correlated (rs=0.515, P < 0.05). Conclusion: The ex＜x＞pression of CTHRC1 and VEGF are up-regulated in ovarian cancer tissues, which may be related to FIGO stage, pathological grade and lymph node me＜x＞tastasis, and the ex＜x＞pression of CTHRC1 and VEGF are positively correlated, is worth further study

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回